Workers Comp Medical Inflation Slows to 1%—But NCCI Warns It Won’t Last

June's 1% Inflation Rate Marks a Sharp Deceleration for Workers Comp Medical Costs

The National Council on Compensation Insurance’s latest weighted medical price index shows that overall workers compensation medical costs in June 2026 were only 1% higher than a year earlier—a dramatic slowdown from the 1.9% average posted over the preceding twelve months and well below the three- and five-year averages of 2.5%.

NCCI cautioned that the softening is likely temporary, projecting that inflation will “move up toward a 2% to 2.5% range over the next several quarters.” Two forces are driving the June moderation: hospital outpatient prices were flat compared to June 2025 after running at roughly 4% annual growth historically, and prescription drug costs fell 2.3% year-over-year.

The drug-price decline, now in its sixth consecutive month, runs counter to earlier tariff-related concerns. NCCI pointed to the Medicare Drug Price Negotiation Program and a proposed federal policy that would cap U.S. drug payments at the lowest price paid by other developed nations as factors that have pushed down prices for many commonly prescribed medications used in workers compensation.

What’s Behind the Slowdown—and Why NCCI Expects It to Reverse

Hospital Outpatient Flatlining After Years of Growth

Hospital outpatient services are the single largest component of workers comp medical spend, and their 0% year-over-year change in June represents a sharp break from the historical 4% annual trend. NCCI’s index, which re-weights national inflation data to reflect the mix of services actually consumed in workers compensation, makes this flattening even more consequential than it would be in general health-care indices. The council did not speculate on the underlying cause, but the abrupt deceleration likely reflects a combination of site-neutral payment shifts, slower utilization growth, or pricing adjustments by large provider networks that heavily serve occupational injury claimants.

Prescription Drug Costs Buck Tariff Worries

Despite earlier fears that new trade tariffs would boost pharmaceutical prices, workers comp drug costs have now fallen for six straight months. NCCI directly credits two government policies: the Medicare Drug Price Negotiation Program, which allows direct negotiation for high-cost drugs, and a proposed international reference pricing rule that would tie U.S. payments to the lowest price in other developed nations. The 2.3% decline in June is meaningful because pharmacy benefits are a high-visibility cost line for insurers and self-insured employers. If the reference-pricing proposal advances, further downward pressure on commonly used anti-inflammatory, pain-management, and specialty medications could extend these savings.

Why NCCI Thinks the Dip Is Temporary

NCCI’s expectation that inflation will drift back to a 2–2.5% range rests on the view that the factors suppressing costs are unlikely to persist at current intensity. Hospital outpatient prices may rebound as contract renegotiations catch up, and drug-price savings tied to policy changes face legislative and legal uncertainty. Additionally, the index’s own five-year average signals that a 1% annual increase is an outlier, not a new equilibrium. For underwriters and claims managers, the key takeaway is that the June data point represents a welcome but probably short-lived reprieve, not a permanent reset of the medical cost trendline.

What This Means for Insurers, Employers and Claims Administrators

• Incorporate NCCI’s index into loss reserving models, but weight the forward 2–2.5% forecast more heavily than the June 1% figure when projecting ultimate claim costs for policies in force.
• For short-term pricing of workers comp policies, the recent softening may support modest rate decreases or dividend plans, but carriers and self-insured employers should avoid locking in rates that assume a sustained 1% medical trend.
• Claims teams should continue aggressive oversight of hospital outpatient charges, as the flattening in June could mask variability across facilities—identify which provider networks delivered the lowest growth and steer injured workers accordingly.
• Monitor the progress of international reference pricing legislation; if enacted, it could permanently lower the pharmacy cost trajectory and justify a revision to long-term drug trend assumptions.
• Employers with large deductibles or self-insured retentions can use this data in renewal negotiations, but should budget for a return to the historical 2.5% range over the next two policy years.